| 1.48 0.02 (1.37%) | 05-22 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.88 | 1-year : | 2.19 |
| Resists | First : | 1.61 | Second : | 1.88 |
| Pivot price | 1.35  |
|||
| Supports | First : | 1.35 | Second : | 1.2 |
| MAs | MA(5) : | 1.47 |
MA(20) : | 1.35 |
| MA(100) : | 1.28  |
MA(250) : | 1.56 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 73.1 |
D(3) : | 74.8 |
| RSI | RSI(14): 59.4 |
|||
| 52-week | High : | 3.58 | Low : | 0.93 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ NNVC ] has closed below upper band by 17.6%. Bollinger Bands are 20.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.51 - 1.52 | 1.52 - 1.52 |
| Low: | 1.41 - 1.42 | 1.42 - 1.42 |
| Close: | 1.47 - 1.48 | 1.48 - 1.49 |
NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
Fri, 16 May 2025
NanoViricides: Fiscal Q3 Earnings Snapshot - Huron Daily Tribune
Thu, 15 May 2025
NanoViricides: Fiscal Q3 Earnings Snapshot - San Francisco Chronicle
Mon, 14 Apr 2025
NanoViricides evaluating antiviral drug NV-387 for measles treatment - Proactive financial news
Fri, 28 Mar 2025
NanoViricides eyes role in US bird flu fight as USDA unveils $100M initiative - Proactive financial news
Fri, 31 Jan 2025
NanoViricides warns of bird flu pandemic as outbreak spreads in Massachusetts - Proactive financial news
Sun, 20 Oct 2024
Interview with the President and Executive Chairman: NanoViricides, Inc. (NYSEAMERICAN:NNVC) - The Wall Street Transcript
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 12 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 4.5 (%) |
| Held by Institutions | 11.3 (%) |
| Shares Short | 473 (K) |
| Shares Short P.Month | 348 (K) |
| EPS | -0.82 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.89 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -40.8 % |
| Return on Equity (ttm) | -65.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.77 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -1.81 |
| PEG Ratio | 0 |
| Price to Book value | 1.64 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.77 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|